文献速递糖尿病

欧米伽-6脂肪酸生物标志物与新发2型糖尿病:20项前瞻性队列研究39 740名成人个体水平数据的汇总分析

Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-10-12

该研究汇总了来自10个国家20项前瞻性队列的39 740名基线无2型糖尿病成人,随访366 073人年期间发生4347例新发2型糖尿病;多变量校正后,亚油酸生物标志物占总脂肪酸比例升高与2型糖尿病风险降低相关,花生四烯酸生物标志物与风险无显著关联。

要点

  • 亚油酸生物标志物占总脂肪酸比例每升高一个五分位间距,2型糖尿病风险比为0.65。
  • 花生四烯酸生物标志物与2型糖尿病风险无显著关联,提示其并非有害。
  • 年龄、BMI、性别、种族、阿司匹林使用、欧米伽-3脂肪酸水平及FADS基因变异均未显著改变上述关联。

核心结论

  • 研究结果提示亚油酸对2型糖尿病预防具有长期益处,且花生四烯酸并非有害。

研究设计与样本

  • 研究为对20项前瞻性队列研究新近统一协调的个体水平数据进行的汇总分析,队列来自10个国家(冰岛、荷兰、美国、台湾、英国、德国、芬兰、澳大利亚、瑞典和法国),生物标志物采样于1970年至2010年间。
  • 纳入分析者为18岁及以上、基线有亚油酸和花生四烯酸生物标志物数据的参与者,并排除基线已患2型糖尿病者;共纳入39 740名成人,队列均值年龄范围49-76岁,队列均值BMI范围23.3-28.4 kg/m2。
  • 各队列各脂质 compartment 分别按预设分析方案前瞻性评估2型糖尿病相对风险,再用逆方差加权荟萃分析汇总结果。

主要发现

  • 随访366 073人年期间共识别4347例新发2型糖尿病。
  • 多变量校正汇总分析中,亚油酸生物标志物占总脂肪酸比例较高与总体2型糖尿病风险降低相关(每五分位间距风险比[RR] 0.65,95% CI 0.60-0.72,p<0.0001;I2=53.9%,异质性p=0.002)。
  • 亚油酸生物标志物与2型糖尿病的关联在不同脂质 compartment(包括磷脂、血浆、胆固醇酯和脂肪组织)中大致相似。
  • 花生四烯酸生物标志物水平与总体2型糖尿病风险无显著关联(每五分位间距RR 0.96,95% CI 0.88-1.05;p=0.38;I2=63.0%,异质性p<0.0001)。
  • 亚油酸和花生四烯酸生物标志物与2型糖尿病风险的关联未被任何预设潜在异质性来源显著修饰(即年龄、BMI、性别、种族、阿司匹林使用、欧米伽-3多不饱和脂肪酸水平或FADS基因变异;所有异质性p≥0.13)。

局限性

  • 亚油酸与2型糖尿病关联的汇总分析存在中等异质性(I2=53.9%,异质性p=0.002)。
  • 花生四烯酸与2型糖尿病关联的汇总分析存在异质性(I2=63.0%,异质性p<0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, and little evidence is available regarding their potential role in primary prevention of type 2 diabetes. We aimed to assess the associations of linoleic acid and arachidonic acid biomarkers with incident type 2 diabetes. METHODS: We did a pooled analysis of new, harmonised, individual-level analyses for the biomarkers linoleic acid and its metabolite arachidonic acid and incident type 2 diabetes. We analysed data from 20 prospective cohort studies from ten countries (Iceland, the Netherlands, the USA, Taiwan, the UK, Germany, Finland, Australia, Sweden, and France), with biomarkers sampled between 1970 and 2010. Participants included in the analyses were aged 18 years or older and had data available for linoleic acid and arachidonic acid biomarkers at baseline. We excluded participants with type 2 diabetes at baseline. The main outcome was the association between omega-6 PUFA biomarkers and incident type 2 diabetes. We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid compartment separately using a prespecified analytic plan for exposures, covariates, effect modifiers, and analysis, and the findings were then pooled using inverse-variance weighted meta-analysis. FINDINGS: Participants were 39 740 adults, aged (range of cohort means) 49-76 years with a BMI (range of cohort means) of 23·3-28·4 kg/m2, who did not have type 2 diabetes at baseline. During a follow-up of 366 073 person-years, we identified 4347 cases of incident type 2 diabetes. In multivariable-adjusted pooled analyses, higher proportions of linoleic acid biomarkers as percentages of total fatty acid were associated with a lower risk of type 2 diabetes overall (risk ratio [RR] per interquintile range 0·65, 95% CI 0·60-0·72, p<0·0001; I2=53·9%, pheterogeneity=0·002). The associations between linoleic acid biomarkers and type 2 diabetes were generally similar in different lipid compartments, including phospholipids, plasma, cholesterol esters, and adipose tissue. Levels of arachidonic acid biomarker were not significantly associated with type 2 diabetes risk overall (RR per interquintile range 0·96, 95% CI 0·88-1·05; p=0·38; I2=63·0%, pheterogeneity<0·0001). The associations between linoleic acid and arachidonic acid biomarkers and the risk of type 2 diabetes were not significantly modified by any prespecified potential sources of heterogeneity (ie, age, BMI, sex, race, aspirin use, omega-3 PUFA levels, or variants of the FADS gene; all pheterogeneity≥0·13). INTERPRETATION: Findings suggest that linoleic acid has long-term benefits for the prevention of type 2 diabetes and that arachidonic acid is not harmful. FUNDING: Funders are shown in the appendix.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Wu JHY, Marklund M, Imamura F, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017. PMID: 29032079. doi:10.1016/S2213-8587(17)30307-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。